To support our hypothesis on the involvement of uc.291 and its competitor ACTL6A in modulating keratinocyte differentiation, we decided to establish an in vitro model of psoriasis by treating differentiated cells with IL-22. This evidence concerns the gene IL22 and psoriasis.